# Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

> **NCT01690299** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 250 (actual)

## Conditions studied

- Psoriasis
- Psoriatic Arthritis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Etanercept
- **DRUG:** Placebo tablet
- **DRUG:** Placebo injection

## Key facts

- **NCT ID:** NCT01690299
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-01
- **Primary completion:** 2014-07-03
- **Final completion:** 2016-04-04
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01690299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01690299, "Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01690299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*